Femto Research Group brings home the Service Innovation of the Year Award

New DBS method will boost its Plasma p53Microbiome innovation.

With only a few drops of blood, the renowned research group can detect somatic mutations in both young and advanced cancer cells, as well as microbial DNA insertions and hidden in human genome.

Thailand's Femto Research Group Co., Ltd prides itself on being the only company that can detect and identify femto-level microbe DNA hidden within our genome, thanks to its Plasma p53Microbiome.

Recognizing this microbe DNA allows people to observe genetic density from only a few drops of blood sample.

Because of this innovation, it is no surprise that Femto Research Group Co., Ltd won the Service Innovation of the Year Award during the recently concluded Healthcare Asia Awards 2019.

The Plasma p53Microbiome is a game changer in the field of cancer research.

As this clinical tool detects microbial DNA insertions, Femto Research Group Co., Ltd is able to determine infectious insertions which can lead to cancer development in non-sick people and recurrence and treatment complication in cancer patients.

Moreover, its ability to identify somatic mutations in the p53 gene is of great importance due to the fact that somatic mutations in said gene are one of the most frequent in human cancers and can resist standard medications and treatments.

The Plasma p53Microbiome greatly benefits cancer patients, cured cancer patients with risk of relapse, as well as non-sick individuals.

This test is expected to be a trailblazing clinical tool to increase the success of both personalised prevention and treatment with non-random precision.

At present, clinical solutions currently practiced for this test include determining cancer patients with severe p53(TP53) damage. Once the damage is identified, patients are advised to avoid certain chemotherapeutic drugs and possibly radiation.

The Plasma p53Microbiome is also being used to target infectious agents to determine which chemical drugs and natural products and supplements can be expected to cure the infection-caused cancer.

Throughout the years, Plasma p53Microbiome needed fresh blood sample to be delivered within 48 hours at 4°C to Femto Lab. This limited the innovator's ability to accept samples from far-flung areas and countries, which in turn inspired them to develop more reliable methods to preserve and transfer blood samples.

After a year of trials, Femto Research Group had a breakthrough with its “dried blood spots (DBS) collection on Whatman filter paper” method, which was initially performed less than 50 years earlier for diagnostic screening, drug monitoring, genetic analysis, and molecular epidemiological studies in remote tropical areas with suboptimal transport and storage conditions.

Because of this, plasma DNA extraction from the DBS at room temperature delivery can now be perfectly used for the Plasma p53Microbiome.

With this innovation, people from all across the world can gain access to and benefit from personalised and precision medicine for early cancer and recurrence prevention as well as advanced cancer treatment.

These Plasma DNA tests are available only at Femto Lab, whilst the “Plasma Microbiome” test is commercially available only at Femto Lab at the global scale.

Watch the interview below to know more about their winning projects:

The Healthcare Asia Awards 2019 was held on May 23, 2019 at the Conrad Centennial Singapore.

This year's nominations were judged by a panel consisting of Abhay Bangi, Partner, Life Sciences & Healthcare Lead, Ernst & Young; Dr. Loke Wait Chiong Executive Director, Healthcare Sector Leader, Deloitte; Dr. Zubin Daruwalla, Director, SEAC Health Industries Leader, PwC; Chin Chee Choon, Advisory Leader, Nexia TS; and Willy Leow, Partner, Risk Advisory Services, BDO LLP.

Check out the event photos during the awards night here.

If you would like to join the 2020 awards and be awarded as one of the most outstanding healthcare companies in the region, please email Julie Anne Nuñez at [email protected].